相关实验视频

Updated: Jun 11, 2025

Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion

Wet Chemistry and Peptide Immobilization on Polytetrafluoroethylene for Improved Cell-adhesion

Published on: August 15, 2016

通过展开延伸改善治疗候选N-TIMP2的循环半衰期

Jason Shirian¹, Alexandra Hockla², Justyna J Gleba²

¹Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.

|September 28, 2024

概括

研究人员通过开发PATylation扩大了金属蛋白酶组织抑制剂 (TIMPs) 的治疗潜力. 这种方法显著增加了小鼠TIMP2 (N-TIMP2) 的N端域的血半衰期,提供了一个有前途的药物开发策略.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
药物开发药物开发

背景情况:

矩阵金属蛋白酶 (MMPs) 与各种疾病有关,特别是癌症.
组织金属蛋白酶抑制剂 (TIMPs) 是具有治疗潜力的天然MMP抑制剂.
由于尺寸小,TIMPs的快速清除限制了它们的临床应用.

研究的目的:

延长TIMP2 (N-TIMP2) 的N端域的血半衰期.
评估PATylation在增强N-TIMP2的药理动力学特性方面的疗效.
为疾病治疗开发改进的抗MMP疗法.

主要方法:

设计和生产了两种PATylated N-TIMP2结构 (N-TIMP2-PAT100和N-TIMP2-PAT200) 具有不同的尾巴长度.
评估了结构的明显分子量和MMP-9抑制活性.
在小鼠体内确定N-TIMP2-PAT200的血半衰期.

主要成果:

这两种PATylated结构都显示出明显增加的分子重量,并保持高的MMP-9抑制活性.
在小鼠中,N-TIMP2-PAT200与非PATylated N-TIMP2相比显示出显著延长的血半衰期.
帕提化证明有效地提高了N-TIMP2.2的药理动力学特征.

结论:

帕提化是一种可行的策略,可以延长N-TIMP2.2的血半衰期.
这种方法提供了诸如遗传编码,单分散和生物降解等优势.
基化N-TIMP2变体作为MMP相关疾病的候选药物具有前景.

关键词:

通过PASylation进行化.这是一种PATylation.时间表 (TIMP)半衰期的延长半衰期的延长矩阵金属蛋白抑制剂矩阵金属蛋白抑制剂治疗性蛋白质治疗性蛋白质

更多相关视频

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation

Published on: August 1, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...